Search results
Results from the WOW.Com Content Network
Coricidin, Coricidin 'D' (decongestant), or Coricidin HBP (for high blood pressure), is the name of an over-the-counter cough and cold drug containing dextromethorphan (a cough suppressant) and chlorpheniramine maleate (an antihistamine). [1] Introduced by Schering-Plough in 1949 as one of the first antihistamines, it is now owned by Bayer.
Guaifenesin/codeine is a fixed-dose combination cold medicine used for the treatment of cough. [1] It contains guaifenesin, an expectorant; and codeine, as the phosphate, an opioid antitussive. [1] It is taken by mouth. [1] It was approved for medical use in the United States in 2006. [1]
Guaifenesin might act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi via stimulation of the gastric mucosa. . This stimulation leads to an increased parasympathetic activity in the respiratory tract via the so-called gastro-pulmonary reflex, although some in vitro studies suggested that it might also act directly on the ...
Ambroxol is a drug that breaks up phlegm, used in the treatment of respiratory diseases associated with viscid or excessive mucus. Ambroxol is often administered as an active ingredient in cough syrup. It was patented in 1966 and came into medical use in 1979. [1]
Phenylpropanolamine (PPA), sold under many brand names, is a sympathomimetic agent used as a decongestant and appetite suppressant. [9] [1] [10] [11] It was once common in prescription and over-the-counter cough and cold preparations. The medication is taken orally. [4] [12] Side effects of phenylpropanolamine include increased heart rate and ...
Dextromethorphan, or DXM, a common active ingredient found in many over-the-counter cough suppressant cold medicines, is used as a recreational drug and entheogen for its dissociative effects. [1] Street names include Brownies , Dextro , Drix , Gel , Groove , Lean , Mega-perls , Poor man's ecstasy , Poor man's PCP, Red devils , Robo , Rojo ...
The FDA's decision gives some breathing room to rival GSK's chronic cough treatment camlipixant, which is in late-stage development with anticipated regulatory approval and launch in 2026.
Bromhexine is intended to support the body's mechanisms for clearing mucus from the respiratory tract.It is secretolytic, increasing the production of serous mucus in the respiratory tract, which makes the phlegm thinner and less viscous.